Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITI-214 CNS Engagement Study in Healthy Volunteers
NCT03489772Phase 1Completed
- Sponsor
- Intra-Cellular Therapies
- Start
- Jul 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of lenrispodun in Parkinson's disease (PD) and schizophrenia, sponsored by Intra-Cellular Therapies. Primary endpoints: BOLD MRI signals in the anterior insula during the extinction phase of a Fear Conditioning task and BOLD MRI signals in the inferior frontal gyrus during the Stop Signal Task. Started Jul 2018; status: completed.
02
Drugs
lenrispodun
03
Conditions
Parkinson's disease (PD)schizophrenia
Beyond the preview
Go deeper on NCT03489772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03489772.